A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

Study sponsor: Rapport Therapeutics Inc. · RAPP

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.